4//SEC Filing
Tessier-Lavigne Marc 4
Accession 0001883850-22-000072
CIK 0000872589other
Filed
Oct 2, 8:00 PM ET
Accepted
Oct 3, 4:05 PM ET
Size
37.5 KB
Accession
0001883850-22-000072
Insider Transaction Report
Form 4
Tessier-Lavigne Marc
Director
Transactions
- Sale
Common Stock
2022-09-29$689.56/sh−1,009$695,766→ 4,084 total - Exercise/Conversion
Common Stock
2022-09-30$413.33/sh+3,428$1,416,895→ 5,697 total - Exercise/Conversion
Common Stock
2022-09-29$413.33/sh+3,798$1,569,827→ 6,067 total - Sale
Common Stock
2022-09-29$687.90/sh−321$220,816→ 5,730 total - Sale
Common Stock
2022-09-29$696.13/sh−85$59,171→ 2,753 total - Sale
Common Stock
2022-09-29$697.29/sh−160$111,566→ 2,593 total - Sale
Common Stock
2022-09-29$686.89/sh−16$10,990→ 6,051 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2022-10-03−3,612→ 0 totalExercise: $413.33Exp: 2025-01-02→ Common Stock (3,612 underlying) - Sale
Common Stock
2022-09-29$688.71/sh−637$438,708→ 5,093 total - Sale
Common Stock
2022-09-29$690.65/sh−692$477,930→ 3,392 total - Sale
Common Stock
2022-09-29$691.59/sh−554$383,141→ 2,838 total - Sale
Common Stock
2022-09-29$699.82/sh−80$55,986→ 2,305 total - Sale
Common Stock
2022-09-29$702.36/sh−16$11,238→ 2,289 total - Sale
Common Stock
2022-09-29$698.44/sh−208$145,276→ 2,385 total - Sale
Common Stock
2022-09-30$698.00/sh−3,428$2,392,744→ 2,269 total - Exercise/Conversion
Common Stock
2022-10-03$413.33/sh+3,612$1,492,948→ 5,881 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2022-09-29−3,798→ 7,040 totalExercise: $413.33Exp: 2025-01-02→ Common Stock (3,798 underlying) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2022-09-30−3,428→ 3,612 totalExercise: $413.33Exp: 2025-01-02→ Common Stock (3,428 underlying) - Sale
Common Stock
2022-09-29$704.83/sh−20$14,097→ 2,269 total - Sale
Common Stock
2022-10-03$718.00/sh−3,612$2,593,416→ 2,269 total
Footnotes (11)
- [F1]Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- [F10]Represents volume-weighted average price of sales of 208 shares of Company stock on September 29, 2022 at prices ranging from $698.19 to $698.71. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price.
- [F11]The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.
- [F2]Represents volume-weighted average price of sales of 16 shares of Company stock on September 29, 2022 at prices ranging from $686.89 to $686.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price.
- [F3]Represents volume-weighted average price of sales of 321 shares of Company stock on September 29, 2022 at prices ranging from $687.05 to $687.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price.
- [F4]Represents volume-weighted average price of sales of 637 shares of Company stock on September 29, 2022 at prices ranging from $688.08 to $688.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price.
- [F5]Represents volume-weighted average price of sales of 1,009 shares of Company stock on September 29, 2022 at prices ranging from $689.07 to $689.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price.
- [F6]Represents volume-weighted average price of sales of 692 shares of Company stock on September 29, 2022 at prices ranging from $690.06 to $690.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price.
- [F7]Represents volume-weighted average price of sales of 554 shares of Company stock on September 29, 2022 at prices ranging from $691.29 to $691.72. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price.
- [F8]Represents volume-weighted average price of sales of 85 shares of Company stock on September 29, 2022 at prices ranging from $696.03 to $696.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price.
- [F9]Represents volume-weighted average price of sales of 160 shares of Company stock on September 29, 2022 at prices ranging from $697.10 to $697.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price.
Documents
Issuer
REGENERON PHARMACEUTICALS, INC.
CIK 0000872589
Entity typeother
Related Parties
1- filerCIK 0001437435
Filing Metadata
- Form type
- 4
- Filed
- Oct 2, 8:00 PM ET
- Accepted
- Oct 3, 4:05 PM ET
- Size
- 37.5 KB